T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer

Completed

• Conditions: Prostate Cancer

• Registration Number: NCT01376674
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.

In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-03
• Study First Submitted: 2011-06-16
• Study First Submitted QC: 2011-06-16
• Study First Posted: 2011-06-20
• Status Verified: 2013-08
• Last Update Submitted: 2013-08-15
• Last Update Posted: 2013-08-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 22

Inclusion Criteria

• Localised prostate cancer (node negative)
• definitive radiotherapy
• informed consent

Exclusion Criteria

• medication including steroids or immunosuppressants

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
T-cell-immunity in time-course	During and 3-6 months after radiotherapy

Trial Locations

Locations (1)

Department of Radiation Oncology; 🇩🇪 Tuebingen, Germany